title: [Antibacterial activities of combination uses of cefpirome with various antibiotics in vitro against clinically isolated glucose non-fermentative gram-negative rods: part 1. the results against Pseudomonas aeruginosa].
abstract: In order to evaluate antibacterial activities of combination uses of cefpirome (CPR) and various antibiotics in vitro, minimum inhibitory concentrations (MICs) of CPR alone and combinations of CPR+other drugs against freshly isolated clinical strains of Pseudomonas aeruginosa. The results are summarized as follows; 1. Combined effects of CPR+beta-lactams, piperacillin (PIPC), aztreonam (AZT), imipenem (IPM) showed wider antibacterial spectra and stronger antibacterial activities than CPR alone with drugs concentrations of CPR and other drugs at sub-MIC levels. At concentrations of sub-MIC levels, antibacterial effects of CPR+PIPC and CPR+AZT combination were strong but CPR+IPM was weaker than those of the former two combinations. It appeared that stronger effects were demonstrated by some combinations against strains that were susceptible to both drugs of combination, but little additive effects were shown against strains that were resistant to both drugs. Antibacterial effect of CPR+fosfomycin combination was the same as those of CPR+PIPC and CPR+AZT combinations. 2. Combined effects of CPR+aminoglycosides (AGs), gentamicin, tobramycin, amikacin showed wider antibacterial spectra and stronger antibacterial activities at sub-MIC levels of CPR or ATs. The effect against CPR-resistant strains was same. But the combined effect was weak against AGs-resistant strains. 3. Effectiveness of combinations of CPR+beta-lactams and CPR+AGs depended on drug susceptibilities of strains tested. We cannot estimate effects of those combinations without investigating drug susceptibility of bacteria being tested. 4. In none of the combinations tested, antagonism was observed.
authors.affiliation: Section of Studies, Tokyo Clinical Research Center.
authors.forename: Y
authors.initials: Y
authors.lastname: Suzuki
authors.forename: M
authors.initials: M
authors.lastname: Koguchi
authors.forename: S
authors.initials: S
authors.lastname: Fukayama
authors.forename: R
authors.initials: R
authors.lastname: Ishihara
authors.forename: S
authors.initials: S
authors.lastname: Oda
authors.forename: K
authors.initials: K
authors.lastname: Deguchi
mesh_terms: D000583:Amikacin / Q000008:administration & dosage; D000900:Anti-Bacterial Agents / Q000008:administration & dosage*; D001398:Aztreonam / Q000008:administration & dosage; D002511:Cephalosporins / Q000008:administration & dosage*; D004338:Drug Combinations; D004357:Drug Synergism; D005839:Gentamicins / Q000008:administration & dosage; D015378:Imipenem / Q000008:administration & dosage; D010878:Piperacillin / Q000008:administration & dosage; D011550:Pseudomonas aeruginosa / Q000187:drug effects*; D014031:Tobramycin / Q000008:administration & dosage; D000097572:Cefpirome
chemical_list: D000583:Amikacin; D000900:Anti-Bacterial Agents; D001398:Aztreonam; D002511:Cephalosporins; D004338:Drug Combinations; D005839:Gentamicins; D015378:Imipenem; D010878:Piperacillin; D014031:Tobramycin; D000097572:Cefpirome